Clinical Trials
7
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1951
Completed
3
42.9%
Terminated
1
14.3%
Unknown
3
42.9%
No approval data available
- New research presented at the FENS Forum 2026 uncovers sex-specific genetic changes in brain cells that may explain why Parkinson's disease is 1.5- to 2-fold more common in men than women. - The study found that while both sexes share common stress responses in brain cells, astrocytes and oligodendrocytes show key differences in gene activity related to mitochondrial function and myelin maintenance. - Women with Parkinson's showed DNA methylation changes in 69 genomic regions compared to only two in men, suggesting genetic makeup strongly influences epigenetic patterns. - Researchers emphasize that analyzing data separately by sex is crucial for developing personalized Parkinson's treatments rather than treating all patients as biologically identical.
- The phase 3 ESOPEC trial demonstrated that perioperative chemotherapy with FLOT significantly improved overall survival compared to neoadjuvant chemoradiation with CROSS in patients with locally advanced esophageal adenocarcinoma. - Patients receiving FLOT achieved a median overall survival of 66 months versus 37 months with CROSS, representing a 30% reduction in death risk with statistical significance. - The study enrolled 438 patients across 25 German centers and showed FLOT also improved progression-free survival and pathological complete response rates. - These findings may establish FLOT as the new standard of care for locally advanced esophageal cancer, though immunotherapy combinations are emerging as additional treatment options.
